Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,844.19
-0.17%
DAX
26,391.42
+0.26%
CAC 40
8,714.94
-0.13%
STOXX 50
6,551.22
+0.24%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

GSK

  • GSK plans to make 1bn coronavirus vaccine booster shots

    May 28, 2020

    Drug giant Glaxosmithkline (GSK) today announced that it would aim to produce 1bn vaccine booster shots next year in a bid to improve the efficacy of potential new coronavirus treatments. These booster shots, which are called adjuvants, are a key part of vaccine development as they help patients develop a longer lasting immunity to disease. [...]

  • GSK beats expectations with strong first quarter performance

    April 29, 2020

    Pharmaceuticals giant Glaxosmithkline (GSK) beat analysts’ expectations with its first quarter results today, and said it remained on course to fulfil its 2020 guidance. The performance, which the firm labelled “strong”, was founded on high demand for its shingles treatment shingrix and higher sales of pain medications during the coronavirus crisis. GSK shares were flat [...]

  • Coronavirus: GSK chief urges drug firms to work together to develop vaccines

    April 15, 2020

    The chief executive of pharmaceuticals giant Glaxosmithkline (GSK) has urged companies to join together to speed the development of a coronavirus vaccine, warning that the world will need more than one treatment for the disease. Emma Walmsley’s words came after the firm announced it had partnered with French drugmaker Sanofi to make a vaccine.  Clinical [...]

  • GSK partners with Sanofi to develop coronavirus vaccine

    April 14, 2020

    Pharmaceuticals giant Glaxosmithkline (GSK) has joined forces with French drugmaker Sanofi to develop a vaccine for the coronavirus disease. The two firms said that they were planning to begin clinical trials for the new treatment in the second half of this year. If successful, it is hoped that the vaccine would become available in the [...]

  • Pharma giant GSK takes $250m stake in firm to develop coronavirus vaccine

    April 7, 2020

    Pharmaceuticals giant Glaxosmithkline (GSK) has taken a $250m (£202.7m) stake in an American biotech company in a collaborative effort to make a vaccine for Covid-19. Vir Biotechnology, of which GSK now owns a 6 per cent stake, specialises in the treatment of severe infectious diseases, and is looking to develop an antibody treatment for the [...]

  • Unilever acquires Horlicks brand in India in £397m deal

    April 1, 2020

    Consumer goods giant Unilever has today completed the acquisition of Horlicks and other Glaxosmithkline brands in a £397m deal. The deal will allow Unilever to use the Horlicks brand rights and other GSK Consumer Healthcare nutrition brands in predominantly Asian markets. The company’s listed subsidiary in India, Hindustan Unilever Limited (Hul) also announced today that [...]

  • GSK falls short of forecasts as firm prepares to split

    February 5, 2020

    Multinational drug firm Glaxosmithkline (GSK) saw a small rise in operating profit and earnings in 2019 as the firm announced it had begun its planned split into two companies following its venture with Pfizer. However, earnings per share fell short of analyst expectations at 123.9p, below consensus estimates of 125p. Pressure on the price of [...]

  • Glaxosmithkline posts third-quarter sales growth after Pfizer purchase

    October 30, 2019

    Glaxosmithkline have reported group sales of £9.4bn for the third quarter, with total operating profits of £2.1m, compared with £1.9m for the same period in 2018. The drug manufacturer raised its forecast for 2019, saying that it now expected profits to be flat compared to last year, up from a previous estimated of a three [...]

  • GSK continues pharmaceuticals push with $1.1bn vaccines sale

    October 21, 2019

    Glaxosmithkline (GSK) has today announced the sale of two travel vaccines worth up to $1.1bn (£846.9m) to Bavarian Nordic, continuing its push into the cancer drug market. The sales of Rabipur, an anti-rabies drug, and Encipur, which is used to prevent encephalitis, to the Denmark-based biotech firm, will include an upfront payment of €301m (£258.5m), [...]

  • GSK eyes former Astrazeneca CFO for empty chair

    July 14, 2019

    Drugmaker Glaxosmithkline is set to announce the former finance boss of Astrazeneca as its new chair to oversee the breakup of the business. GSK is preparing to appoint Jonathan Symonds as its new non-executive chair, Sky News reported earlier. Read more: GSK to split as it forms £9.8bn consumer health venture with Pfizer The announcement [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • …
  • Page 22
  • Next

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook